Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: Final results from the EGF104900 study

Kimberly L. Blackwell, Harold J. Burstein, Anna Maria Storniolo, Hope S. Rugo, George Sledge, Gursel Aktan, Catherine Ellis, Allison Florance, Svetislava Vukelja, Joachim Bischoff, José Baselga, Joyce O'Shaughnessy

Research output: Contribution to journalArticle

359 Citations (Scopus)

Abstract

Purpose: Phase III EGF104900 data demonstrated that lapatinib plus trastuzumab significantly improved progression-free survival (PFS) and clinical benefit rate versus lapatinib monotherapy, offering a chemotherapy-free option for patients with heavily pretreated human epidermal growth factor receptor 2 (HER2) -positive metastatic breast cancer (MBC). Final planned overall survival (OS) analysis from EGF104900 is reported here. Patients and Methods: Patients with HER2-positive MBC whose disease progressed during prior trastuzumab-based therapies were randomly assigned to receive lapatinib monotherapy or lapatinib in combination with trastuzumab. OS and updated PFS data are presented using Kaplan-Meier curves and log-rank tests stratified for hormone receptor and visceral disease status. Subgroup analyses were conducted to identify characteristics of patients deriving the greatest clinical benefit. Results: In this updated final analysis of all patients randomly assigned with strata (n = 291), lapatinib plus trastuzumab continued to show superiority to lapatinib monotherapy in PFS (hazard ratio [HR], 0.74; 95% CI, 0.58 to 0.94; P = .011) and offered significant OS benefit (HR, 0.74; 95% CI, 0.57 to 0.97; P = .026). Improvements in absolute OS rates were 10% at 6 months and 15% at 12 months in the combination arm compared with the monotherapy arm. Multiple baseline factors, including Eastern Cooperative Oncology Group performance status of 0, nonvisceral disease, < three metastatic sites, and less time from initial diagnosis until random assignment, were associated with improved OS. Incidence of adverse events was consistent with previously reported rates. Conclusion: These data demonstrated a significant 4.5-month median OS advantage with the lapatinib and trastuzumab combination and support dual HER2 blockade in patients with heavily pretreated HER2-positive MBC.

Original languageEnglish
Pages (from-to)2585-2592
Number of pages8
JournalJournal of Clinical Oncology
Volume30
Issue number21
DOIs
StatePublished - Jul 20 2012

Fingerprint

Breast Neoplasms
Survival
Disease-Free Survival
Survival Analysis
human ERBB2 protein
lapatinib
Trastuzumab
Survival Rate
Hormones
Drug Therapy
Incidence
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer : Final results from the EGF104900 study. / Blackwell, Kimberly L.; Burstein, Harold J.; Storniolo, Anna Maria; Rugo, Hope S.; Sledge, George; Aktan, Gursel; Ellis, Catherine; Florance, Allison; Vukelja, Svetislava; Bischoff, Joachim; Baselga, José; O'Shaughnessy, Joyce.

In: Journal of Clinical Oncology, Vol. 30, No. 21, 20.07.2012, p. 2585-2592.

Research output: Contribution to journalArticle

Blackwell, Kimberly L. ; Burstein, Harold J. ; Storniolo, Anna Maria ; Rugo, Hope S. ; Sledge, George ; Aktan, Gursel ; Ellis, Catherine ; Florance, Allison ; Vukelja, Svetislava ; Bischoff, Joachim ; Baselga, José ; O'Shaughnessy, Joyce. / Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer : Final results from the EGF104900 study. In: Journal of Clinical Oncology. 2012 ; Vol. 30, No. 21. pp. 2585-2592.
@article{7655da2dfa83479c90b8075cc3dd1d5c,
title = "Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: Final results from the EGF104900 study",
abstract = "Purpose: Phase III EGF104900 data demonstrated that lapatinib plus trastuzumab significantly improved progression-free survival (PFS) and clinical benefit rate versus lapatinib monotherapy, offering a chemotherapy-free option for patients with heavily pretreated human epidermal growth factor receptor 2 (HER2) -positive metastatic breast cancer (MBC). Final planned overall survival (OS) analysis from EGF104900 is reported here. Patients and Methods: Patients with HER2-positive MBC whose disease progressed during prior trastuzumab-based therapies were randomly assigned to receive lapatinib monotherapy or lapatinib in combination with trastuzumab. OS and updated PFS data are presented using Kaplan-Meier curves and log-rank tests stratified for hormone receptor and visceral disease status. Subgroup analyses were conducted to identify characteristics of patients deriving the greatest clinical benefit. Results: In this updated final analysis of all patients randomly assigned with strata (n = 291), lapatinib plus trastuzumab continued to show superiority to lapatinib monotherapy in PFS (hazard ratio [HR], 0.74; 95{\%} CI, 0.58 to 0.94; P = .011) and offered significant OS benefit (HR, 0.74; 95{\%} CI, 0.57 to 0.97; P = .026). Improvements in absolute OS rates were 10{\%} at 6 months and 15{\%} at 12 months in the combination arm compared with the monotherapy arm. Multiple baseline factors, including Eastern Cooperative Oncology Group performance status of 0, nonvisceral disease, < three metastatic sites, and less time from initial diagnosis until random assignment, were associated with improved OS. Incidence of adverse events was consistent with previously reported rates. Conclusion: These data demonstrated a significant 4.5-month median OS advantage with the lapatinib and trastuzumab combination and support dual HER2 blockade in patients with heavily pretreated HER2-positive MBC.",
author = "Blackwell, {Kimberly L.} and Burstein, {Harold J.} and Storniolo, {Anna Maria} and Rugo, {Hope S.} and George Sledge and Gursel Aktan and Catherine Ellis and Allison Florance and Svetislava Vukelja and Joachim Bischoff and Jos{\'e} Baselga and Joyce O'Shaughnessy",
year = "2012",
month = "7",
day = "20",
doi = "10.1200/JCO.2011.35.6725",
language = "English",
volume = "30",
pages = "2585--2592",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "21",

}

TY - JOUR

T1 - Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer

T2 - Final results from the EGF104900 study

AU - Blackwell, Kimberly L.

AU - Burstein, Harold J.

AU - Storniolo, Anna Maria

AU - Rugo, Hope S.

AU - Sledge, George

AU - Aktan, Gursel

AU - Ellis, Catherine

AU - Florance, Allison

AU - Vukelja, Svetislava

AU - Bischoff, Joachim

AU - Baselga, José

AU - O'Shaughnessy, Joyce

PY - 2012/7/20

Y1 - 2012/7/20

N2 - Purpose: Phase III EGF104900 data demonstrated that lapatinib plus trastuzumab significantly improved progression-free survival (PFS) and clinical benefit rate versus lapatinib monotherapy, offering a chemotherapy-free option for patients with heavily pretreated human epidermal growth factor receptor 2 (HER2) -positive metastatic breast cancer (MBC). Final planned overall survival (OS) analysis from EGF104900 is reported here. Patients and Methods: Patients with HER2-positive MBC whose disease progressed during prior trastuzumab-based therapies were randomly assigned to receive lapatinib monotherapy or lapatinib in combination with trastuzumab. OS and updated PFS data are presented using Kaplan-Meier curves and log-rank tests stratified for hormone receptor and visceral disease status. Subgroup analyses were conducted to identify characteristics of patients deriving the greatest clinical benefit. Results: In this updated final analysis of all patients randomly assigned with strata (n = 291), lapatinib plus trastuzumab continued to show superiority to lapatinib monotherapy in PFS (hazard ratio [HR], 0.74; 95% CI, 0.58 to 0.94; P = .011) and offered significant OS benefit (HR, 0.74; 95% CI, 0.57 to 0.97; P = .026). Improvements in absolute OS rates were 10% at 6 months and 15% at 12 months in the combination arm compared with the monotherapy arm. Multiple baseline factors, including Eastern Cooperative Oncology Group performance status of 0, nonvisceral disease, < three metastatic sites, and less time from initial diagnosis until random assignment, were associated with improved OS. Incidence of adverse events was consistent with previously reported rates. Conclusion: These data demonstrated a significant 4.5-month median OS advantage with the lapatinib and trastuzumab combination and support dual HER2 blockade in patients with heavily pretreated HER2-positive MBC.

AB - Purpose: Phase III EGF104900 data demonstrated that lapatinib plus trastuzumab significantly improved progression-free survival (PFS) and clinical benefit rate versus lapatinib monotherapy, offering a chemotherapy-free option for patients with heavily pretreated human epidermal growth factor receptor 2 (HER2) -positive metastatic breast cancer (MBC). Final planned overall survival (OS) analysis from EGF104900 is reported here. Patients and Methods: Patients with HER2-positive MBC whose disease progressed during prior trastuzumab-based therapies were randomly assigned to receive lapatinib monotherapy or lapatinib in combination with trastuzumab. OS and updated PFS data are presented using Kaplan-Meier curves and log-rank tests stratified for hormone receptor and visceral disease status. Subgroup analyses were conducted to identify characteristics of patients deriving the greatest clinical benefit. Results: In this updated final analysis of all patients randomly assigned with strata (n = 291), lapatinib plus trastuzumab continued to show superiority to lapatinib monotherapy in PFS (hazard ratio [HR], 0.74; 95% CI, 0.58 to 0.94; P = .011) and offered significant OS benefit (HR, 0.74; 95% CI, 0.57 to 0.97; P = .026). Improvements in absolute OS rates were 10% at 6 months and 15% at 12 months in the combination arm compared with the monotherapy arm. Multiple baseline factors, including Eastern Cooperative Oncology Group performance status of 0, nonvisceral disease, < three metastatic sites, and less time from initial diagnosis until random assignment, were associated with improved OS. Incidence of adverse events was consistent with previously reported rates. Conclusion: These data demonstrated a significant 4.5-month median OS advantage with the lapatinib and trastuzumab combination and support dual HER2 blockade in patients with heavily pretreated HER2-positive MBC.

UR - http://www.scopus.com/inward/record.url?scp=84864066561&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864066561&partnerID=8YFLogxK

U2 - 10.1200/JCO.2011.35.6725

DO - 10.1200/JCO.2011.35.6725

M3 - Article

C2 - 22689807

AN - SCOPUS:84864066561

VL - 30

SP - 2585

EP - 2592

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 21

ER -